120 related articles for article (PubMed ID: 17044194)
1. The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma.
Davidson B; Risberg B; Berner A; Bedrossian CW; Reich R
Semin Diagn Pathol; 2006 Feb; 23(1):35-43. PubMed ID: 17044194
[TBL] [Abstract][Full Text] [Related]
2. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma.
Davidson B; Zhang Z; Kleinberg L; Li M; Flørenes VA; Wang TL; Shih IeM
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):5944-50. PubMed ID: 17062665
[TBL] [Abstract][Full Text] [Related]
3. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells.
Davidson B; Baekelandt M; Shih IeM
Diagn Cytopathol; 2007 Dec; 35(12):756-60. PubMed ID: 18008338
[TBL] [Abstract][Full Text] [Related]
4. Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma.
Brusegard K; Stavnes HT; Nymoen DA; Flatmark K; Trope CG; Davidson B
Virchows Arch; 2012 Feb; 460(2):193-202. PubMed ID: 22249560
[TBL] [Abstract][Full Text] [Related]
5. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
[TBL] [Abstract][Full Text] [Related]
6. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas.
Ordóñez NG
Hum Pathol; 2005 Nov; 36(11):1163-7. PubMed ID: 16260268
[TBL] [Abstract][Full Text] [Related]
7. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
[TBL] [Abstract][Full Text] [Related]
8. Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma.
Andrici J; Jung J; Sheen A; D'Urso L; Sioson L; Pickett J; Parkhill TR; Verdonk B; Wardell KL; Singh A; Clarkson A; Watson N; Toon CW; Gill AJ
Hum Pathol; 2016 May; 51():9-15. PubMed ID: 27067777
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic challenge of peritoneal mesothelioma.
Krasuski P; Poniecka A; Gal E
Arch Gynecol Obstet; 2002 Jul; 266(3):130-2. PubMed ID: 12197549
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions.
Davidson B; Reich R; Kopolovic J; Berner A; Nesland JM; Kristensen GB; Tropé CG; Bryne M; Risberg B; van de Putte G; Goldberg I
Clin Exp Metastasis; 2002; 19(2):135-44. PubMed ID: 11964077
[TBL] [Abstract][Full Text] [Related]
11. Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma.
Davidson B; Vintman L; Zcharia E; Bedrossian C; Berner A; Nielsen S; Ilan N; Vlodavsky I; Reich R
Clin Exp Metastasis; 2004; 21(5):469-76. PubMed ID: 15672872
[TBL] [Abstract][Full Text] [Related]
12. PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma.
Brenne K; Nymoen DA; Reich R; Davidson B
Am J Clin Pathol; 2012 Feb; 137(2):240-7. PubMed ID: 22261449
[TBL] [Abstract][Full Text] [Related]
13. The differential diagnosis of primary peritoneal papillary tumors.
Gitsch G; Tabery U; Feigl W; Breitenecker G
Arch Gynecol Obstet; 1992; 251(3):139-44. PubMed ID: 1376598
[TBL] [Abstract][Full Text] [Related]
14. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas.
Ordóñez NG
Am J Surg Pathol; 1998 Oct; 22(10):1203-14. PubMed ID: 9777982
[TBL] [Abstract][Full Text] [Related]
15. Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma.
Khalifeh I; Munkarah AR; Lonardo F; Malone JM; Morris R; Lawrence WD; Ali-Fehmi R
Int J Gynecol Pathol; 2004 Apr; 23(2):162-9. PubMed ID: 15084845
[TBL] [Abstract][Full Text] [Related]
16. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients.
Davidson B; Lazarovici P; Ezersky A; Nesland JM; Berner A; Risberg B; Tropé CG; Kristensen GB; Goscinski M; van de Putte G; Reich R
Clin Cancer Res; 2001 Nov; 7(11):3457-64. PubMed ID: 11705863
[TBL] [Abstract][Full Text] [Related]
17. Is PAX2 a reliable marker in differentiating diffuse malignant mesotheliomas of peritoneum from serous carcinomas of müllerian origin?
Gao FF; Krasinskas AM; Chivukula M
Appl Immunohistochem Mol Morphol; 2012 May; 20(3):272-6. PubMed ID: 22498671
[TBL] [Abstract][Full Text] [Related]
18. Malignant peritoneal mesothelioma presented as peritoneal adenocarcinoma or primary ovarian cancer: case series and review of the clinical and immunohistochemical features.
Taşkın S; Gümüş Y; Kiremitçi S; Kahraman K; Sertçelik A; Ortaç F
Int J Clin Exp Pathol; 2012; 5(5):472-8. PubMed ID: 22808303
[TBL] [Abstract][Full Text] [Related]
19. p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer.
Ito T; Hamasaki M; Matsumoto S; Hiroshima K; Tsujimura T; Kawai T; Shimao Y; Marutsuka K; Moriguchi S; Maruyama R; Miyamoto S; Nabeshima K
Am J Clin Pathol; 2015 Jun; 143(6):830-8. PubMed ID: 25972325
[TBL] [Abstract][Full Text] [Related]
20. Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma.
Vettukattil R; Hetland TE; Flørenes VA; Kærn J; Davidson B; Bathen TF
Hum Pathol; 2013 Sep; 44(9):1859-66. PubMed ID: 23656974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
